¼±Åà - È»ìǥŰ/¿£ÅÍŰ
´Ý±â - ESC
KMLE °Ë»ö
°Ë»ö ¼³Á¤
¿Â¶óÀÎ ÀÇÇмÀû
ÀÇÇпë¾î »çÀü
ÀÇÇоà¾î
ÀÇÇлçÀü
ÇÑ¿µ/¿µÇÑ»çÀü
¿µ¿µ»çÀü
»çÀÌÆ® ¼Ò°³
Àç°Ë»ö
"Acquired coagulation factor deficiency"¿¡ ´ëÇÑ ´ëÇÑÀÇÇù ÀÇÇпë¾î ¼¼ºÎ °Ë»ö °á°úÀÔ´Ï´Ù
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
nutritional deficiency syndrome
¿µ¾ç°áÇÌÁõÈıº
vitamin deficiency
ºñŸ¹Î°áÇÌ(Áõ)
acquired
1. ÈÄõ- 2. ȹµæ-
acquired blindness
ÈÄõ½Ã°¢»ó½Ç, ÈÄõ½Ç¸í
acquired character
ÈÄõÇüÁú
acquired cystic kidney disease
ÈÄõ³¶¼ºÄáÆÏº´, ÈÄõ³¶¼º½ÅÀ庴
acquired deafness
ÈÄõ³Ã»
acquired ichthyosis
ÈÄõºñ´ÃÁõ
acquired immunity
ÈÄõ¸é¿ª
acquired immunodeficiency syndrome
ÈÄõ¸é¿ª°áÇÌÁõÈıº, ¿¡ÀÌÁî
acquired megacolon
ÈÄõ°Å´ëÀß·ÏâÀÚ, ÈÄõ°Å´ë°áÀå
acquired perforating dermatosis
ÈÄõõ°øÇǺκ´
acquired progressive lymphangioma
ÈÄõÁøÇาÇÁ°üÁ¾
acquired resistance
ȹµæÀúÇ×
acquired tolerance
ȹµæ³»¼º
ÀÌÀü
´ÙÀ½
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
14
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
intrinsic factor
³»ÀÎÀÎÀÚ, ³»ÀÎÀÚ
nerve growth factor
½Å°æ¼ºÀåÀÎÀÚ
platelet activating factor
Ç÷¼ÒÆÇȰ¼ºÀÎÀÚ
platelet-derived growth factor
Ç÷¼ÒÆÇÀ¯·¡¼ºÀåÀÎÀÚ, Ç÷¼ÒÆÇ±â¿ø¼ºÀåÀÎÀÚ
precipitation factor
ÃËÁø¿äÀÎ
predisposing factor
¼±Çà¿äÀÎ
prognostic factor
¿¹ÈÄÀÎÀÚ
psychological factor
½É¸®¿ä¼Ò
relaxing factor
ÀÌ¿ÏÀÎÀÚ
resistance factor
³»¼ºÀÎÀÚ, °ßµõÀÎÀÚ
rheumatoid factor
·ù¸¶Æ¼½ºÀÎÀÚ
risk factor
À§ÇèÀÎÀÚ
transforming growth factor
Àüȯ¼ºÀåÀÎÀÚ
vascular endothelial growth factor
Ç÷°ü³»ÇǼºÀåÀÎÀÚ
ÀÌÀü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
acquired immunodeficiency syndrome
ÈÄõ¸é¿ª°áÇÌÁõÈıº, ¿¡ÀÌÁî
acquired perforating dermatosis
ÈÄõõ°øÇǺκ´
acquired progressive lymphangioma
ÈÄõÁøÇาÇÁ°üÁ¾
hospital acquired infection
¿ø³»°¨¿°, º´¿ø°¨¿°
activated coagulation time
Ȱ¼ºÇ÷¾×ÀÀ°í½Ã°£
blood coagulation
Ç÷¾×ÀÀ°í
blood coagulation mechanism
Ç÷¾×ÀÀ°í±âÀü
blood coagulation test
Ç÷¾×ÀÀ°í°Ë»ç
coagulation
ÀÀ°í
coagulation disorder
ÀÀ°íÀå¾Ö
coagulation necrosis
ÀÀ°í±«»ç
coagulation pathway
ÀÀ°í°æ·Î
coagulation time
ÀÀ°í½Ã°£
diffuse intravascular coagulation
¹Ì¸¸Ç÷°ü³»ÀÀ°í
disseminated intravascular coagulation
ÆÄÁ¾Ç÷°ü³»ÀÀ°í
ÀÌÀü
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
acquired color vision defect
ÈÄõ»ö°¢ÀÌ»ó
acquired cystic disease of the kidney
ÈÄõ¼º ½Å³¶Æ÷Áúȯ
acquired deafness
ÈÄõ(¼º) ³Ã» ³ó
acquired digital fibrokeratoma
ÈÄõ¼º ¼Õ¹ß°¡¶ô ¼¶À¯ °¢ÈÁ¾
acquired disease
ÈÄõ¼º Áúº´(¡òðÜ»).
acquired heart disease =AHD
ÈÄõ¼º ½ÉÁúȯ(¡ãýòðü´).
acquired hyperoxaluria
ÈÄõ¼º °í¼ö»ê´¢Áõ
acquired ichthyosis
ÈÄõ¼º(ýô¸àõ)¾î¸°¼±(åà×÷àÈ)
acquired immunity
ÈÄõ¼º ¸é¿ª, ½Å°æÈ¹µæ¸é¿ª(üòÔðØóæ¹).
acquired immunodeficiency syndorme
ÈÄõ¼º ¸é¿ª°áÇÌ ÁõÈıº(ýô¸àõ Øóæ¹ÌÀù¹ ñøý¦ÏØ)
acquired immunodeficiency syndrome
ÈÄõ¼º¸é¿ª°áÇÌÁõ
acquired immunodeficiency syndrome
ÈÄõ¼º ¸é¿ª°áÇÌ ÁõÈıº
acquired immunodeficiency syndrome (AIDS)
ÈÄõ¼º¸é¿ª°áÇÌÁõ(Èıº)
acquired immunodeficiency syndrome(AIDS)
ÈÄõ¼º ¸é¿ª°áÇÌ ÁõÈıº
acquired perforating dermatosis
ÈÄõ¼º õ°ø¼º ÇǺκ´
ÀÌÀü
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
col factor(»ýÈ) cÀÌ ÀÎÀÚ colicin factor
Äݸ®½ÅÀÎÀÚ.
lupus erythematosus factor = LE factor
È«¹Ý¼º ·çǪ½ºÀÎÀÚ(ûõÚèàõ¡ì×í)
time, dose and fractionation factor, TDF factor
½Ã°£¼±·®ºÐÇÒÀÎÀÚ
acquired
ÈÄõ¼ºÀÇ
acquired B
ȹµæ B Çü
acquired angioedema
ÈÄõ¼º(ýô¸àõ) ¸Æ°üºÎÁ¾(ØæÎ·Ý©ðþ)
acquired blindness
ÈÄõ¸Í.
acquired character
ÈÄõÇüÁú(¡û¡òõ).
acquired color vision defect
ÈÄõ»ö°¢ÀÌ»ó
acquired cystic disease of the kidney
ÈÄõ¼º ½Å³¶Æ÷Áúȯ
acquired deafness
ÈÄõ(¼º) ³Ã» ³ó
acquired digital fibrokeratoma
ÈÄõ¼º ¼Õ¹ß°¡¶ô ¼¶À¯ °¢ÈÁ¾
acquired disease
ÈÄõ¼º Áúº´(¡òðÜ»).
acquired heart disease =AHD
ÈÄõ¼º ½ÉÁúȯ(¡ãýòðü´).
acquired hyperoxaluria
ÈÄõ¼º °í¼ö»ê´¢Áõ
ÀÌÀü
´ÙÀ½
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
ÀÌÀü
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
ÀÌÀü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
ÀÌÀü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
ÀÌÀü
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
2
¿µ¹®
ÇѱÛ
ÀÌÀü
ÅëÇÕ°Ë»ö ¿Ï·á
ÀÌÀü
´ÙÀ½